Evidence map›Paper›PMID 30408566›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Sarah A Holstein, J Christine Ye, Alan Howard, Manisha Bhutani, Nicole Gormley, Theresa Hahn, Jens Hillengass, Amrita Krishnan, C Ola Landgren, Nikhil C Munshi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Review
  7. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sarah A HolsteinDepartment of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: sarah.holstein@unmc.edu.
J Christine YeDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
Alan HowardCenter for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
Manisha BhutaniDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, North Carolina.
Nicole GormleyUS Food and Drug Administration, Silver Spring, Maryland.
Theresa HahnThe Transplant & Cellular Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Jens HillengassThe Transplant & Cellular Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Amrita KrishnanDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
C Ola LandgrenDepartment of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Nikhil C MunshiLeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Boston, Massachusetts.
Stefania OlivaDivision of Hematology, Myeloma Unit, University of Torino, Torino, Italy.
Roger G OwenHaematological Malignancy Diagnostic Service, St James's Institute of Oncology, Leeds, United Kingdom.
Marcelo C PasquiniDepartment of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Noemi PuigDepartment of Hematology, Universit Hospital of Salamanca, Salamanca, Spain.
Niels WeinholdMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Katja WeiselDepartment of Hematology, Oncology, Immunology and Rheumatology, Universitatsklinikum Tubingen, Tubingen, Germany.
Philip L McCarthyThe Transplant & Cellular Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
City of Hope Core Clinical Center for the Blood and Marrow Transplant Clinical Trials NetworkUG1HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI RYOTARO NAKAMURA · 2017 to 2026
$2.2M
MSKCC BMT CTN RenewalUG1HL069315 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI MIGUEL-ANGEL PERALES · 2017 to 2026
$2.2M
BMT CTN Core - Dana-Farber Cancer Institute and MGH ConsortiumUG1HL069249 · NHLBI · DANA-FARBER CANCER INST · PI Mahasweta Gooptu · 2017 to 2026
$2.2M
Ancillary Studies in Clinical Trials - PRIMeRR01HL107213 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HAHN, THERESA E, PASQUINI, MARCELO C. · 2011 to 2014
$1.5M
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL107213NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069249NHLBI NIH HHS UG1 HL069278NHLBI NIH HHS UG1 HL069315
6 · The paper itself

Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

Indexed as

Bone Marrow TransplantationCongresses as TopicEducationImmunologic FactorsNeoplasm, ResidualClinical Trials as TopicHumansMultiple MyelomaSocieties, ScientificImmunologic FactorsAutologous stem cell transplantationEndpointImmune profilingMinimal residual diseaseMultiple myeloma

Identifiers

PMID30408566
PMCPMC6445685

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.